The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
4-((5-methyl-4-((2-oxo-2,3-dihydrobenzo[d]oxazol5-yl)amino)pyrimidin-2yl)amino)benzenesulfonamide ID: ALA5204045
PubChem CID: 168293798
Max Phase: Preclinical
Molecular Formula: C18H16N6O4S
Molecular Weight: 412.43
Associated Items:
Names and Identifiers Canonical SMILES: Cc1cnc(Nc2ccc(S(N)(=O)=O)cc2)nc1Nc1ccc2oc(=O)[nH]c2c1
Standard InChI: InChI=1S/C18H16N6O4S/c1-10-9-20-17(22-11-2-5-13(6-3-11)29(19,26)27)24-16(10)21-12-4-7-15-14(8-12)23-18(25)28-15/h2-9H,1H3,(H,23,25)(H2,19,26,27)(H2,20,21,22,24)
Standard InChI Key: DGEHHFSIVHNINC-UHFFFAOYSA-N
Molfile:
RDKit 2D
29 32 0 0 0 0 0 0 0 0999 V2000
-5.3904 -0.4210 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-4.5654 -0.4210 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.0946 -1.0747 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-3.2904 -0.8246 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.2904 0.0006 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.0734 0.2466 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-2.5802 0.4125 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.8638 0.0043 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.8638 -0.8241 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.5784 -1.2365 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.1493 -1.2366 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.4346 -0.8241 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.2827 -1.2384 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.9943 -0.8220 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.7088 -1.2345 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.4232 -0.8220 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.1408 -1.2363 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.8509 -0.8199 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.8509 0.0010 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.1362 0.4136 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.4232 0.0030 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.5654 0.4134 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
4.5654 1.2384 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
4.9787 -0.3023 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
5.3904 0.4134 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
0.9943 -0.0011 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.2780 0.4114 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.4346 0.0008 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.1490 0.4134 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 1 0
4 3 1 0
5 4 2 0
5 6 1 0
6 2 1 0
7 5 1 0
8 7 2 0
9 8 1 0
10 9 2 0
4 10 1 0
9 11 1 0
11 12 1 0
12 13 1 0
13 14 2 0
14 15 1 0
15 16 1 0
16 17 1 0
17 18 2 0
18 19 1 0
19 20 2 0
20 21 1 0
21 16 2 0
19 22 1 0
22 23 1 0
22 24 2 0
22 25 2 0
14 26 1 0
26 27 2 0
27 28 1 0
28 12 2 0
28 29 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 412.43Molecular Weight (Monoisotopic): 412.0954AlogP: 2.35#Rotatable Bonds: 5Polar Surface Area: 156.00Molecular Species: NEUTRALHBA: 8HBD: 4#RO5 Violations: ┄HBA (Lipinski): 10HBD (Lipinski): 5#RO5 Violations (Lipinski): ┄CX Acidic pKa: 9.42CX Basic pKa: 4.16CX LogP: 2.68CX LogD: 2.68Aromatic Rings: 4Heavy Atoms: 29QED Weighted: 0.39Np Likeness Score: -1.37
References 1. Chen Y, Li H, Yen R, Heckrodt TJ, McMurtrie D, Singh R, Taylor V, Masuda ES, Park G, Payan DG.. (2022) Optimization of Pyrimidine Compounds as Potent JAK1 Inhibitors and the Discovery of R507 as a Clinical Candidate., 13 (11.0): [PMID:36385926 ] [10.1021/acsmedchemlett.2c00411 ]